基于细菌纳米纤维素和奇托桑的粘膜囊作为黄提取物输送系统
Laia Posada1, Natalia Jaramillo-Quiceno1, Cristina Castro1
1School of Engineering, Universidad Pontificia Bolivariana, Circular 1°, No. 70-01, Medellín, 050031, Colombia.
Heliyon
|November 30, 2023
概括
研究人员使用细菌纳米纤维素和奇托桑开发了粘膜囊,用于向胃药物输送. 这个系统增强了药物的生物可用性,并显示出治疗癌症等胃疾病的潜力.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 胃肠病学 胃肠病学
背景情况:
- 提高药物在胃中的生物可用性是药物设计的一个关键挑战.
- 细菌纳米纤维素 (BNC) 是一种有前途的药物输送材料,但缺乏胃粘附.
- 低分子量奇托 (LMWC) 具有粘粘性,可以增强胃内.
研究的目的:
- 从BNC涂上交叉连接的LMWC开发粘膜囊,用于向的胃药物输送.
- 描述开发的囊的粘膜和物理性质.
- 评估该系统为胃癌化学预防提供生物活性化合物的潜力.
主要方法:
- 用交叉连接的LMWC涂层的BNC囊的制造.
- 使用扫描电子显微镜,红外光谱和热重力测量分析进行表征.
- 用黄提取物 (TE) 进行粘粘度评估和药物加载/释放研究.
主要成果:
- 交叉链接的奇托桑在酸性条件下显示增强胀.
- 桑涂层提高了BNC囊的热稳定性.
- 囊在胃环境中表现出显著的粘粘度 (89.151 ± 6.226 mN).
- 黄提取物得到控制的吸附和脱附.
结论:
- 结合BNC和LMWC的粘膜囊为向胃药物输送提供了一个有希望的平台.
- 该系统显示了增强胃病治疗疗效的潜力,包括胃癌.
- 这种方法促进了为胃量身定制的药物输送系统的开发.
相关概念视频
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...


